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Abstract 
 
Zoonotic diseases are diseases caused by microorganisms which spread naturally from animals to 
humans. Humans have been plagued by these types of diseases since the dawn of humankind. Zoonotic 
diseases account for approximately 61% of all human diseases and it has been found that about 75% of 
emerging diseases are zoonotic-derived. With the current rise in the global human population, zoonotic 
diseases are becoming increasingly prevalent. Many factors contribute to the prevalence of zoonotic 
diseases, including the encroachment by humans into animal habitat, increased livestock production, and 
increased mixing of different animal species. In addition, with the improvements in global travel, an 
isolated zoonotic event has the potential to become a global pandemic within a relatively short period of 
time. In order to get a good understanding of how a zoonotic event occurs, it is important to understand 
both the animal and human aspect of the particular disease. A better understanding and overlap between 
human and animal medicine is key in reducing the prevalence of zoonotic diseases.   This paper will 
specifically study Lyme disease, a vector-borne disease prevalent in New England, as an example to 
explain how human and animal health play a role in the spread of a zoonotic disease.   
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Introduction  
 
While most people are fully aware of the benefits of having a household pet, few people are 
aware of the diseases they can contract from their companion animals or that their pets can become 
infected with some of the same diseases humans do. These diseases are known as Zoonotic diseases, also 
called zoonoses, and they are caused by microorganisms that can infect both animals and humans (Torrey, 
2005). Zoonoses account for approximately 61% of all human diseases and it has been found that about 
75% of emerging diseases are zoonotic (Torrey, 2005).  Emerging diseases are defined as “diseases that 
have appeared for the first time, or are increasing in incidence, or have been reported in new areas,” 
(Cleaveland, 2001). 
Throughout time, Zoonotic diseases have had a profound impact on human history. From the 
moment that we evolved into modern man, we carried with us infections agents that came from our 
animal counterparts. As we evolved, disease causing microorganisms, known as pathogens, also evolved 
within animal reservoirs; some of these pathogens were able to make the jump from animal to human 
hosts. Some of the most historical and devastating pandemics can be attributed these types of animal 
derived pathogens, most notably bacterial and viral pathogens due to their rapid reproductive cycles 
(Torrey, 2005). Zoonoses have been a problem for as long as we have coexisted with animals (after all we 
are animals ourselves).  Initially, we acquired infections from wild animals that we came in contact with. 
The earliest mode of transmission were heirloom infections, in which microorganisms were passed from 
prehistoric animals, to early primates, then on to early hominoids, and finally to humans. The origins of 
diseases such as malaria and hepatitis A and B date back to prehistoric times and are examples of 
heirloom infections (Torrey, 2005).      
Early humans lived in small nomadic hunter-gatherer societies who followed herds of animals. 
Their diet consisted mostly of available plants and some animal meat. Their nomadic lifestyle did not 
allow them to accumulate waste products that would harbor problematic species, like rats. By observing 
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modern day hunter-gatherers, we know that they lived generally healthy lifestyles without major life 
threatening infections. As humans shifted towards agricultural communities, diseases became more 
abundant. We bred animals for livestock and our abundance of crops and organic waste attracted wild 
animals to move closer to our civilizations. These factors lead to an increase in the prevalence of Zoonotic 
diseases within the human population (“The Natural History of Disease”).  
Throughout history, animals and humans have shared a close relationship with each other. Certain 
animals, both domestic and wild, transmit diseases to us more readily than others. Our pets and livestock 
like dogs, cats, rabbits, cows, pigs, and birds are prime transmitters of zoonotic infections. In fact, 43% of 
zoonoses we are battling today are acquired from domesticated household pets like cats and dogs, and 
39% account for zoonotic diseases transmitted by livestock such as horses, cattle, sheep, goats and pigs 
(Torrey, 2005).  
Wild animals that are considered pests, like rodents, have fed off of our waste and brought us 
disease for millennia. Rodents have been a reservoir for ancient zoonotic diseases like rabies 
(Rhabdoviridae), Hemorrhagic fevers (Bunyaviridae Hantavirus), and plague (Yesinia pestis) (“The 
Natural History of Disease”). By far the most infamous case of plague, and the most destructive 
pandemic in human history, was the “Black Death” of the 14th century. Strains of Yesinia pestis bacteria 
that caused both bubonic and pneumonic plague spread throughout Europe and Asia during the middle 
ages. The bacteria were responsible for the death of one third of the entire human population at that time 
(Chamberlain, 2010).  Y. pestis was able to proliferate within rodents, but the pathogen’s main source of 
transmission to humans was through a vector organism, the flea (“Plague”, CDC). Fleas acted as vectors 
that acquired the plague causing bacteria from rodents and would then transmit the bacteria to humans. At 
that point in human history we understood little about how microbial infections spread and we lacked 
basic hygienic practices. However as technologies improved, zoonotic pathogens improved and evolved 
too.     
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Primates are our closest relatives and have a great affinity to produce zoonotics. Higher-primates, 
or simians, are related closely to us evolutionarily and have many of the same anatomical and 
biochemical features as we do. Therefore, the gap for a simian pathogen to jump to a human host is 
smaller compared to other animals. The most profound case of a simian derived zoonotic disease that 
became a global pandemic is the Human Immunodeficiency Virus (HIV) outbreak. HIV was thought to 
have evolved from a similar virus that infected primates known as Simian Immunodeficiency Virus (SIV) 
(Wolfe, 1998). This African variant of HIV in primates was able to cross species from primates to 
humans, and now the virus can be transmitted from person to person which has lead to the globalization 
of AIDS, the syndrome caused by an HIV infection.  
 Even with our advancements in the understanding and treatment of infectious diseases, it seems 
that zoonotic pathogens continue to evolve around our understanding of them. So the question still 
remains, how can we control the spread of zoonotic diseases?  One obstacle that we must overcome is 
understanding exactly how and why a pathogen makes the jump from an animal to a human host. Most 
people are aware that zoonoses can spread through direct transmission through an animal bite, scratch, or 
by inhaling the infectious microorganism. This is perhaps the most preventable form of transmission and 
examples include rabies, cat-scratch disease, and anthrax (Torrey, 2005). Indirect transmission of 
zoonoses, spread of microorganisms through food or water contamination, is much more difficult to 
control due to the expansive transportation, distribution of food products, and the lack of clean water and 
sanitary food in many countries throughout the world.  Contamination of meat products and vegetables 
has lead to many outbreaks of E. coli, salmonella, and mad cow disease (Torrey, 2005). An even more 
difficult and threatening mode of zoonotic transmission, and one that is making headlines everywhere, is 
the “animal to human to human” transmission. These infections jump from animals to humans and can 
then be spread from person to person. H1N1, commonly known as “swine flu”, is a reemerging strain of 
influenza which originated in pigs and then made the jump to humans. However now it has the ability to 
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spread amongst the human population (CDC, 2009). Other examples of this type of transmission include 
SARS and other strains of influenza, like H5N1 the “bird flu” virus (Torrey, 2005).  
One of the most difficult modes of zoonotic transmission to control is the realm of vector-borne 
diseases. The diseases involve a secondary organism, typically an insect or parasite like fleas, flies, ticks, 
and mosquitoes, which become infected with a pathogen from an animal and then passes on that pathogen 
to a human host (Torrey, 2005). In New England, one of the most rapidly expanding vector borne diseases 
is Lyme disease. Since the realm of zoonotic diseases can cover an extremely broad range of topics, we 
have chosen to look specifically at Lyme disease as a specific case study; not only due to its relevance in 
New England, but also because it is a relatively new emerging zoonotic disease that is on the rise in both 
humans and animals alike.  
History of Lyme  
 
The tick-borne illness we now refer to as Lyme disease was first identified in 1975 by Allen 
Steere from Yale University after an outbreak of juvenile rheumatoid arthritis in Lyme, Connecticut 
(Appel, 2002). A few years later in 1982 the pathogen that causes Lyme disease, Borrelia burgdorferi, 
was discovered by Dr. Willy Burgdorfer.  The disease has been in existence since the 1880’s in Europe 
but was not fully understood and characterized until the 1970’s. By 1983, physicians had begun treated 
patients who tested positive for Lyme disease with oral and intravenous antibiotic therapy. The vaccine 
for Lyme disease called LYMErix was approved by the FDA in 1998 but taken off the market just three 
years later (Nigrovic and Thompson, 2007).  
 Since the disease was fully characterized in 1982, over 150,000 cases of Lyme disease have been 
reported to the Center for Disease Control and Prevention. The upper East coast, upper Midwest near the 
Great Lakes, the Oregon coast, and Northern California are areas of the United States that have 
experienced concentrated occurrences of Lyme disease, however in total 46 of all 50 states have had 
reported cases of the disease (Acha, 2001). The United States is the largest endemic area of Lyme disease 
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infections and 90% of all reported cases of Lyme disease occur in the 10 states that constitute the 
Northeast region of the U.S. (Appel, 2002). Lyme disease has also been identified in 68 countries 
worldwide, some of the more prominent regions being many countries in Europe, Australia, China, Japan, 
and parts of Russia. The disease has highest incidence during the summer months of June and July in the 
Northern Hemisphere (Acha, 2001).  
 
Figure 1. Map of United States Showing Prevalence of Lyme Disease in Humans.                    
http://www.aldf.com/usmap.shtml. 
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Lyme disease Transmission 
 
Lyme disease is the most common tick-borne disease in the United States. The disease is 
a multisystem inflammatory disease which has the ability to spread from the skin to joints and 
nervous system and even potentially affect other vital organ systems. Humans, horses, and dogs 
are able to contract the vector-borne disease which is transmitted by deer ticks (Ixodes 
scapularis). Deer ticks have a two year life cycle and just one female tick is capable of producing 
approximately 2000 eggs each spring (Appel, 2002).  
 
Figure 2. Female Tick with her Eggs.                                                                                                                                               
http://www.bada-uk.org/images/tick%20eggs.jpg. 
 
These eggs grow into larvae which afterwards develop into nymphs. The nymphs lie 
dormant until late fall when they mature into adults, however even nymphs are able to transmit 
Borrelia burgdorferi  but only at an infection rate of about 10-25% whereas the adult tick 
infection rate is 60% (Appel, 2002).   
7 
 
 
Figure 3. Life Cycle of the Deer Tick                                             
http://www.eradicatelymedisease.org/lyme.html.  
White-footed mice and deer act as the reservoir animals for the disease, and once a tick has bitten 
either of these animals they have then acquired the B. burgdorferi bacteria and are then capable of passing 
it on to other species or animals (Figure 4). The bacteria must move from the ticks mid gut to their 
salivary glands in order to infect an animal and this process normally takes about 24 to 48 hours (Appel, 
2002). Borrelia burgdorferi is a spirochete gram negative bacterium which is closely related to the 
bacteria which also cause leptospirosis and syphilis (Appel, 2002). 
      
Figure 4. Reservoir Animals of Lyme Disease; the White-Footed Mouse and White-Tailed Deer.  
http://www.texasbeyondhistory.net/st-plains/nature/images/deer.html. 
http://www.nature.com/nature/journal/v423/n6938/fig_tab/423397a_F2.html. 
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Immunology & Modes of infection 
 
Borrelia burgdorferi, the spirochete that causes Lyme disease, has the ability to trigger multiple 
clinical symptoms throughout all of the stages of the disease. During the early localization phase of 
infection the bacteria tend to stay close to the point of entry, the tick-bite, and infect the surround skin 
tissue causing rashes and inflammation. Once the bacteria migrate to the blood stream in the early 
dissemination phase, they travel throughout the body and begin to infect multiple tissues groups. The 
early systemic infection typically affects the tissues of the heart, joints, eyes, peripheral nerves, and 
cerebrospinal fluid (Sigal, 2007). If the infection persists into the late phase of the disease the bacteria will 
continue to damage the skin tissue, synovial fluid, and nerve tissue.  
 
Figure 5. "The Transmission of Borrelia burgdorferi to the Mammalian Host and the Dissemination of the Spirochete to 
the Joint.." Nature Reviews, Immunology.  
http://www.nature.com/nri/journal/v4/n2/fig_tab/nri1267_F1.html. 
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B. burgdorferi, like most other infectious bacteria, has an arsenal of cell surface molecules that 
they use to successfully infiltrate the host organism. The bacteria’s entry into the host begins with the 
attachment of the vector, in this case and infectious tick. The tick itself can increase the virulence of B. 
burgdorferi by secreting saliva rich in anticoagulants and anti-inflammatory molecules into the bite-site 
(Sigal, 2007). This allows the tick to receive a continual flow of blood, but it also provides a “smoke-
screen” for the bacteria to enter the body undetected. Once the bacteria enter the dermal layer they begin 
to radiate outwards within the dermis. This radiation of the bacteria within the dermal layer is what causes 
the indicative erythema migrans rash (Sigal, 2007). The spirochete bacteria migrate through the skin by 
associating with host plasminogen. Plasminogen is the precursor to plasmin, a protolitic enzyme that 
degrades fibrin in the blood (Hu, 1995). The plasminogen associated with the bacteria gets activated into 
plasmin by urokinase-type plasminogen activator. The active plasmin allows the bacteria to penetrate 
through the endothelial cells and move into the bloodstream. The presence of B. burgdorferi in the blood 
is known as spirochetemia (Sigal, 2007).  
Once the bacteria become systemic they can penetrate further into their target tissues by 
associating with extracellular matrix (ECM) complexes located on platelets and endothelial cells that line 
the blood vessels. The bacteria penetrate the endothelial layer into their target tissue by binding to cell 
surface proteoglycans, like heparin, via a glycosaminoglycan receptor (Sigal, 2007). The bacteria also 
bind to α2bβ3 intergin on the surface of both the platelets and endothelial cells, and this may play a role in 
increasing spirochetemia (Sigal, 2007). 
  Once the bacteria have successfully made it to their target tissues, typically joint fluid and 
connective tissue, they cause further pathogenesis by anchoring to fibrous proteins associated with the 
ECM of these tissues. The spirochetes are able to associate indirectly with collagen fibers by binding to 
decorin, a glycosaminoglycan molecule that binds directly to collagen, through a bacterial receptor known 
simply as the decorin binding protein (“Pathogenesis”, Brown University). The bacteria can also bind 
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indirectly to other ECM components by anchoring to fibronectin. The full pathogenesis of B. burgdorferi 
is outlined in (Figure 6). 
The surface proteins of B. burgdorferi play an important role in helping the bacteria proliferate 
within the host organism; however, they can also act as antigens that elicit an immune response. The most 
notable antigens are the class of bacterial outer surface proteins (Osp). There are 7 known Osp molecules, 
A-G, and they carry out various functions. For example, association between plasminogen and B. 
burgdorferi is mediated OspA (Sigal, 2007). The expression of these Osp proteins can vary depending on 
environmental and pathogenic conditions (Figure 7).   
 
 
Figure 6. "Expression of B. burgdorferi Outer Surface Proteins." Rocky Mountain Laboratories.  
http://iai.asm.org/content/vol76/issue5/cover.dtl. 
 
 
OspA and OspB are both expressed in spirochetes located in the mid-gut of unfed Ixodes 
scapularis nymphs, whereas OspC and OspD are almost exclusively expressed in spirochetes within the 
host organism.  
The expressions of surface proteins on the cell surface of the bacteria vary between tick and 
mammalian hosts (Figure 8A). OspA proteins are heavily expressed in spirochetes that reside on unfed 
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ticks. However once the tick makes contact with the host blood, Osp A is down regulated and OspC 
becomes heavily expressed (Bunikis, 2003).  
In addition to the outer surface proteins, B. burgdorferi also expresses p66 and p13, short 
transmembrane proteins that are displayed in the surface of the bacteria. Both p66 and p13 can act as 
immune system antigens, however they are often shielded from antibody attachment by the larger outer 
surface proteins (Figure 8B) (Bunikis, 2003).  
 
Figure 7. "A Model of the Outer Membrane of B. burgdorferi." Structure and Function of the Surface Proteins of Borrelia 
Spirochetes .  
http://www.zooeco.org/zooeco/soczee/meetings/CRTBI/abstract/bunikis.asp. 
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Lyme Disease in Humans 
 
Clinical Signs & Symptoms of Lyme Disease in Humans  
 
The symptoms in Lyme disease patients share many similarities to those of arthritis patients. In 
fact, the discovery of the disease was initially reported as multiple cases of ‘juvenile rheumatoid arthritis 
in Lyme, Connecticut (Nigrovic, 2007). These cases later turned out to be caused not by an autoimmune 
condition, but by a bacterial infection. The development of Lyme disease can be broken up into three 
phases ("Lyme Disease – Symptoms", Arthritis Health Center). Phase one is the early localization of the 
infection. This initially takes place at the site of the tick bite where the Borrelia bacteria have entered the 
body. A very common symptom in the early onset of the disease is the formation of a circular “bull’s-
eye” shaped rash, known as an erythema migrans, around the tick-bite (Figure 10). The rash typically 
appears 3-30 days prior to exposure and occurs in approximately 70-80% of Lyme disease cases ("Lyme 
Disease Symptoms", CDC). Even though the erythema migrans rash is considered a tell-tale sign of Lyme 
disease, not all infected persons develop it.    
 
Figure 8. "Erythema Migrans." Lyme Disease rash. 
https://hvelink.saintlukeshealthsystem.org/library/healthguide/en-
us/support/topic.asp?hwid=zm6245. 
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Other common non-specific symptoms in the early localization of the infection include chronic 
fatigue, fever, chills, swollen lymph nodes, joint pain, and stiffness of the neck ("Lyme Disease – 
Symptoms", Arthritis Health Center).  
The second phase in the progression of the disease is early dissemination of the infection. In this 
phase the Borrelia bacteria begin to infect other tissue groups and spread throughout the body. This later 
onset of the disease is often allowed to occur when patients do not exhibit any of the early localized 
symptoms, like erythema migrans, or do not have severe enough symptoms to seek treatment initially. 
Symptoms of early dissemination of the infection include an exacerbation of the early localized symptoms 
and the onset of additional neurological and muscular symptoms, most notably numbness of the 
extremities and paralysis of the facial nerves, known as facial palsy (Figure 11). Patients in the early 
dissemination phase of the disease may also develop conjunctivitis ("Lyme Disease – Symptoms", 
Arthritis Health Center).  
 
Figure 9. "Bell's  (facial) Palsy." 
http://www.beliefnet.com/healthandhealing/getcontent.aspx?cid=12019. 
 
 
The third phase in the development of the disease is the late dissemination phase. Here the 
bacteria cause further joint and nerve damage. Approximately 60% of the patients who enter the chronic 
phase have severe arthritis and inflammation of the joints, especially in the large joints like the knee 
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("Lyme Disease Symptoms", CDC). Patients also experience sharp pains, increased numbness of the 
extremities, and short term memory loss.    
Diagnostic Testing for Lyme disease in Humans   
 
Testing for Lyme disease has raised many questions as to the sensitivity and specificity of the 
diagnostics currently in use. When a person presents with symptoms typical of Lyme disease, the 
physician attending them would run either an Indirect Fluorescent Antibody (IFA) test, or more 
commonly, an Enzyme-linked Immunosorbent Assay (ELISA). Both of these tests detect antibodies for 
Borrelia burgdorferi (“Lyme Disease Diagnostics” CDC, 2009). These two serological tests are meant to 
be very sensitive. Once a positive result is acquired from either of these two tests, a Western Blot is 
performed for better specificity in terms of the stage of the disease. The Western Blot tests for the levels 
of IgM and IgG antibodies in the blood.  The IgM antibody is the first line of defense but will not peak 
until three to six weeks after the patient has been infected, and peak IgG levels are reached later, months 
to years after the onset of the disease (“Lyme Disease Diagnostics” CDC, 2009).  . Due to the length of 
time required to see an immune response, many patients who have been infected will go weeks without 
being treated. This lapse in detecting the IgG and IgM antibodies contributes to the issue of early 
detection of Lyme disease. If a negative Western Blot result is received, then the initial positive result was 
a false positive.  
 
Figure 10. IgM and IgG Antibodies which are recruited during an Immune response to a B. burgdorferi infection. 
http://www.cartage.org.lb/en/themes/sciences/lifescience/GeneralBiology/Physiology/Lymphatic
System/Antibodymediated/Antibodymediated.htm. 
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Many false positives are experienced using the antibody testing method however because it is 
such a sensitive test, so other methods have been explored. Antigen testing experiments have been 
completed to test whether or not this form of diagnostic testing would be a more specific and more 
sensitive method than antibody testing. Antigen tests are considered a more direct method of diagnosis 
than antibody testing. This method proved to be more sensitive than antibody testing but less specific. 
The method is superior to an ELISA test however for diagnosing early stage Lyme disease. It is also 
useful in recognizing false-positive ELISA tests. The drawback that will prevent this method from 
becoming more widely used is the more in depth protocol required for antigen testing (Magnarelli, 1987).   
Treatment of Lyme Disease in Humans   
 
 Since Lyme disease is caused by bacteria, antibiotics are used to eradicate the spirochete bacteria 
from the body. Lyme disease is treatable in most stages of the disease with the proper dosage of 
antibiotics administered orally or intravenously. Exactly which antibiotic is used differs for adults and 
children and also depends how far the disease has progressed in the individual. Specific antibiotics used 
for different stages of the disease are outlined in Table 1. If the disease is caught early, the most likely 
course of treatment in adults is an oral regiment of doxycycline. For children younger than nine years old 
and women who are pregnant, penicillin, amoxicillin, and erythromycin are all effective alternatives to 
the oral doxycycline treatment. In many cases an early course of antibiotics within 72 hours post-infection 
can completely eliminate the development of the disease (Nigrovic, 2007). An intravenous regiment of 
antibiotics may be administered to patients who do not respond to the initial oral antibiotic regiment or in 
patients who present with chronic symptoms of Lyme disease.   
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Table 1. Treatment Regimens for Lyme disease in Humans 
© 2010 Johns Hopkins School of Medicine: Arthritis Center  
 
Early Infection - (Local or Disseminated) 
Adults Doxycycline, 100 mg orally 2 times/days(d) for 20 to 20d 
Amoxicillin, 500 mg orally 3 times/d for 20 to 30d  
Alternatives in case of doxycycline or amoxicillin allergy: 
Cefuroxime axetil, 500 mg orally twice daily for 20 to 30d 
Erythromycin, 150 mg orally 4 times a day or 20 mg/kg/d in 
divided doses for 20 to 20d 
Children 
(Age 8 or less) 
Amoxicillin, 250 mg orally 3 times a day or 20 mg/kg/d in divided 
doses for 20 to 30d  
Alternatives in case of penicillin allergy: 
Cefuroxime axetil, 125 mg orally twice daily for 20 to 30 d 
Erythromycin, 250 mg orally 3 times a day or 30 mg/kg/d in 
divided doses for 20 to 20 d 
Arthritis 
(Intermittent or 
Chronic) 
Doxycycline 100 mg orally 2 times/d for 30 to 60d 
Amoxicilln 500 mg orally 4 times/d for 30 to 60d 
or Ceftriaxone 2g IV once a day for 14 to 39d 
Penicillin G, 20 million U IV in 4 divided doses daily for 30d 
Neurologic Abnormalities 
(Early or Late) Ceftriaxone, 2g IV once a day for 14 to 30d 
Penicillin G, 20 million U IV in 4 divided doses for 30 d  
Alternative in case of ceftriaxone or penicillin allergy: 
Doxycycline, 100 mg orally 3 times a day for 30d 
Facial palsy alone Oral regimens may be adequate 
Cardiac Abnormalities 
First-degree AV block 
(P-R interval >0.3 sec) 
Oral regimens, as for early infection 
High-degree AV block Ceftriaxone, 2 gm IV once a day for 30d** 
Penicillin G, 20 million U IV in 4 divided doses daily for 30d** 
      
 
Lyme Vaccination for Humans 
 
Once Lyme disease was recognized as a bacterial infection in 1977 a demand for a vaccine 
against the bacteria arose. Pharmaceutical companies began to develop vaccines that would expose the 
body’s immune system to some of the bacterial surface proteins. The obvious target for a vaccine would 
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be the characteristic B. burgdorferi outer surface proteins. In the early 90’s two major vaccines were 
developed, LYMErix™ and ImuLyme™, that both used an OspA recombinants as the immugen 
(Nigrovic, 2007). Both immunizations went into clinical trial and showed success in both animal and 
human test subjects. In 1998 LYMErix™ gained FDA approval and went into clinical practice. 
ImuLyme™ never sought FDA approval, even after success in clinical trials (Nigrovic, 2007). 
Although this seemed like a great victory against limiting the spread of Lyme disease, the 
LYMErix™ vaccine ended up being a catastrophic failure and it was pulled from the market in 2002 
(Nigrovic, 2007). There were many factors that limited the success of the Lyme disease vaccine. One of 
the key limitations in the vaccine was that it required multiple inoculations in order to be effective. The 
vaccine would be administered a total of three times (initial inoculation [i], [i]+1 month, and [i]+ 12 
months) in order for patients to receive full immunity (Nigrovic, 2007). Most patients looking to be 
vaccinated, want a “quick-fix”, and do not want the hassle of having to return to the doctor’s office for 
multiple vaccinations. Patients having to receive multiple inoculations also meant that there was a latent 
period where the patients were “partially immune” and still susceptible to infection. Another limitation in 
the success of the vaccine was that it was only 80% effective, which meant that 20% of the people who 
received the full immunization treatment were still at risk (Nigrovic, 2007). Because the vaccination 
lacked strong effectiveness, it actually contributed to the increased prevalence on the disease. 
Unsuccessfully immunized patients gained a false sense of security and ignored simple preventive 
measured when they went into tick infested areas. Other downfalls in the success of the vaccine were that 
its effectiveness in young children, a high risk demographic for contracting Lyme disease, was unknown, 
and the vaccine was only effective against the North American strain of  B. burgdorferi not similar 
European spirochetes (Nigrovic, 2007). 
The vaccine’s poor success was due to both scientific barriers and human behavioral problems. 
From a behavioral perspective, people simply aren’t highly concerned about Lyme disease. Although the 
disease causes devastating symptoms, it is seldom fatal and typically responds well to antibiotic treatment 
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if it is caught early. Also, shortly after the vaccine was licensed by the FDA, there were multiple reported 
cases of autoimmune side-effects like arthritis, after patients had received the vaccine. The FDA 
investigated these allegations and found no substantial evidence to revoke the vaccine’s license (Nigrovic, 
2007). In 1999, a Philadelphia law-firm went on to file a class-action lawsuit against 
SmithKlineBeecham, the company that manufactured LYMErix™, claiming that 121 people who 
received the vaccine suffered multiple adverse side effects (Nigrovic, 2007). This had huge effects on the 
credibility and public opinion of the vaccine. To make matters worse, LYMErix™ was released in the 
middle of an anti-vaccination movement in the US, which caused the media to negatively portray the 
fledgling vaccine (Nigrovic, 2007). In lieu of the pending lawsuit, unpopularity, and low profit margins 
associated with the vaccine SmithKlineBeecham ceased production of the LIMErix™ vaccine in 2002.       
A current vaccine is being developed against B. burgdorferi OspC (Earnhart, 2007). The original 
vaccines against OspA were designed to attach the spirochetes that expressed OspA in the tick’s midgut. 
Since OspC is expressed more than OspA in spirochetes located in the host’s plasma, the OspC vaccine 
should be more effective than the OspA vaccine. However after the catastrophic failure of the first Lyme 
disease vaccine, most pharmaceutical companies are steering clear from Lyme disease specific treatments, 
for fear of releasing the next LYMErix™.      
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Canine Lyme Disease 
 
Clinical Signs Symptoms of Lyme Disease in Dogs 
 
 The first suggestion that dogs could also contract Lyme disease through tick exposure occurred in 
1984 and 1985 (Littman, 2006). In contrast to human response to Borrelia burgdorferi, dogs’ immune 
systems take much longer to respond to spirochete infection. Due to this latent exposure period, dogs will 
not develop symptoms to the bacteria for weeks to months after the initial exposure. Most cases of canine 
Lyme disease are reported during the summer or early fall because the dogs have been exposed during the 
spring or summer at some point. Only 10% of humans infected with B. burgdorferi are asymptomatic as 
opposed to 95% of infected dogs who are asymptomatic (Veterinary Partner, 2010).  Another difference 
between Lyme disease in humans and dogs is the prevalence in the U.S. As you can see from the map 
below (Figure 11) which compares human and dog Borrelia burgdorferi infection, Lyme infection in dogs 
is much more widespread than it is in humans. Although it is most prevalent in the Northeast region, 
Lyme disease does occur elsewhere in the country. The main symptoms associated with Lyme disease in 
dogs are lameness or arthritis, anorexia, and fever. However these symptoms are also common clinical 
signs for other tick-borne diseases such as Rocky Mountain spotted fever, Anaplasmosis, and Ehrlichiosis 
(Littman, 2006). In order to differentiate between Lyme disease and other tick-borne illnesses, diagnostic 
testing is required.  
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Figure 11. Map of the United States Comparing Prevalence of Lyme disease in Humans and Dogs by Region.  
http://underourskin.com/blog/?p=337. 
 
 Untreated Lyme disease in dogs can lead to a condition known as Glomerular disease in which 
excessive amounts of protein are being excreted in the urine. The immune system is trying to fight off the 
B. burgdorferi infection and remove the bacteria from the body. In the process, antibodies end up 
accumulating in the kidneys and can cause damage. To test a Lyme positive dog to see if they are losing 
extra protein in their urine a urinalysis is done. A urine sample is gathered from the dog and a urine 
protein to creatinine ratio test is performed. This test compares the amount of protein and creatinine being 
excreted in the urine in the form of a ratio and indicates whether or not too much protein is being lost in 
the urine. If a dog is losing excess protein in their urine this could lead to kidney disease and in time 
develop into renal failure (Veterinary Partner, 2010). This is the major, long term health concern with 
dogs that test positive for Lyme disease.  
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The steps that should be followed when diagnosing a dog that may have Lyme disease are: 
I. Evidence of Exposure to Borrelia burgdorferi 
A. Positive 4DX or 3DX test 
B. C6 qualitative test to show level of infection  
II. Clinical signs typical of Lyme disease  
A. Lameness 
B. Arthritis 
C. Anorexia  
D. Fever 
III. Consideration of other possible causes of symptoms 
A. Anaplasmosis 
B. Erhlichiosis 
C. Rocky Mountain Spotted Fever 
IV. Response to treatment 
A. Most Lyme positive dogs will respond to treatment with Doxycycline within two 
days of starting the medication (Littman, 2006).  
In addition to these steps diagnostic testing should also be done to verify that it is in fact Lyme disease 
and rule out other possible diseases with similar symptoms.  
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Figure 12. Flowchart of How to Treat and Test a Lyme Positive Dog.  
http://www3.interscience.wiley.com/cgi-bin/fulltext/120715308/PDFSTART. 
Diagnostic Testing for Lyme disease in Dogs 
 
 The greatest challenge that small animal veterinarians are met with when treating dogs in areas 
endemic for Lyme disease, is that about 90% of dogs in that area will have developed antibodies against 
the Lyme spirochete (“Lyme Disease,” Veterinary Partner).  This is due to the fact that many dogs may 
have been bitten by a deer tick and be exposed to the spirochete, but do not have a full blown immune 
response to the infection. These dogs have essentially, immunized themselves to the disease by being 
bitten by the tick and not having the tick intact for a long enough period of time that the spirochete was 
able to completely transfer to its new host. These antibodies the dogs have developed due to that small 
amount of exposure will last for years afterwards (“Lyme Disease,” Veterinary Partner).  
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 There are a few ways of testing for Lyme disease. However many of these methods are difficult, 
time-consuming and expensive so normally faster and easier methods are utilized in a clinical setting. 
Enzyme-linked immunosorbent assays (ELISAs) and Indirect Fluorescent Antibody Assays are two types 
of antibody tests that detect B. burgdorferi in the blood serum. However, these antibody tests are not 
typically utilized in clinics because most dogs will not exhibit clinical signs of infection for a few months 
after infection, and therefore the IgM and IgG antibodies on is full blown (Grodzicki, 1988). Whereas 
ELISA tests give a qualitative result, positive or negative, Western blots allow medical professionals is 
more specific and quantitative, allowing one to see how many antibodies are directed against each 
pathogen. Western Blots with a variety of antigens are useful for differentiating the source of the antibody 
response. Bands in the p58, p37, p35, and p30 areas have been shown to indicate a dog that was infected 
through exposure to a tick and who had never received a Lyme vaccine.  When the p93, p34, p31, and p28 
bands appears on a Western Blot, it is an indication of a dog that has been vaccinated, not infected 
through a tick bite (Guerra, 2000).  
 
Figure 13. The Inf. Lane on the left hand side of the Westernblot indicates that the result for a dog who had naturally been 
infected in an endemic area. The Vac. Lane indicates the result for a dog who had received the Lyme vaccine and lived in an 
endemic area. The Inf. + Vac. Lane indicates a dog that had been vaccinated but did not live in an endemic area.  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC86982/. 
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 When a dog presents to a small animal veterinarian with the classic Lyme symptoms, the next 
step the veterinarian would normally take is performing a blood test. In most clinics 3DX or 4DX is used 
to test for Lyme disease, along with two other common tick-borne diseases and possibly even heartworm. 
Whole blood is used for the test and the blood is mixed with a conjugate and then transferred into a “Snap 
test.” This is an in-house test which takes a total of approximately 10 minutes for results (“Snap 4DX 
Test,” IDEXX).  The result of this test simply indicates whether or not the C6 peptides that indicate a 
natural Lyme infection are present. However this only results in a qualitative test result, whether or not 
C6 peptide is in the blood, and does not specify the level of infection. Antibodies against the C6 peptide 
can be detected within three to five weeks of infection and a positive result will normally occur if the dog 
is retested afterwards for up to 69 weeks (Magnarelli, 1987).   
 
Figure 14. Snap 3DX/ 4DX Test used to Test Dogs for Lyme Disease.  
http://www.idexx.com/view/xhtml/en_us/smallanimal/inhouse/snap/common/technology.jsf.  
25 
 
 
Once a positive result for Lyme disease is procured, a follow up test is performed which is called 
a C6 quantitative test to test the level of antibodies in the blood. Quantifying the level of antibodies 
developed against the spirochete gives the practitioner a better idea of the specificity and severity of the 
infection.  The test analyzes the antibodies produced against the C6 peptide, which is a part of a surface 
antigen of Borrelia burgdorferi (“Lyme Disease,” Veterinary Partner). A significant C6 result is a 
quantity greater than 30U/ml antibody level (“Snap 4DX Test,” IDEXX). This method of Lyme disease 
detection is useful because the C6 peptide is not found in the Lyme vaccine administered to dogs (“Lyme 
Disease,” Veterinary Partner).  This means that a true Borrelia burgdorferi infection and an immunization 
response will not be confused because a vaccinated dog will not test positive. This also eliminates the 
possibility of a dog testing positive because of other underlying health issues. This test is specific to 
Lyme disease only (“Lyme Disease,” Veterinary Partner). The C6 quantitative test does need to be sent 
out to a diagnostic lab and results are typically acquired within 48 hours.  
In addition to getting a quantitative idea of the level of infection, most veterinarians will also 
recommend running some blood work to make sure that the immune system is operating properly to fight 
off the Borrelia burgdorferi infection. These blood tests with also indicate whether or not there are other 
underlying health concerns related to the Lyme disease (Dr. Battiston, 2010).  
Treatment of Canine Lyme Disease 
 
 Once Lyme disease has been detected in a dog who has presented with the typical clinical 
symptoms of Lyme, an antibiotic regimen is prescribed. The most commonly used antibiotic is 
Doxycycline, 10 mg/kg by mouth once daily for approximately 30 days. Doxycycline is from the family 
of tetracycline antibiotics which inhibit protein synthesis of bacteria. These types of antibiotics also are 
effective against a great variety of gram-negative and gram-positive bacteria (Chopra, 2001). This 
antibiotic is also chosen frequently because it can take care of other tick-borne infections as well. 
Doxycycline is inexpensive and has anti-inflammatory properties to help with any joint swelling as result 
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of infection (Littman, 2006). After a day or two of being on Doxycycline, most dogs show much 
improvement. If the dog has a bad reaction to the Doxycycline, amoxicillin can be substituted as 
antibiotic therapy. However, because the Borrelia burgodorferi bacterium is so good at hiding within the 
cells, even after an antibiotic regimen, most dogs will test positive for the infection.  Once a dog tests 
positive for Lyme, the owner is recommended to bring their dog in every 6 months (for the rest of the 
dog’s life) for a recheck of the C6 quantitative test and a urinalysis (Littman, 2006).  
Prevention of Lyme disease in Dogs 
 
 Tick control in endemic areas is not only important for the prevention of Lyme but is also 
essential to prevent infection with other tick-borne diseases. Although these prevention methods may be 
costly, it has been shown that using multiple methods or products together works best for Lyme disease 
prevention. The easiest form of tick control is a tick collar such as a PreventicTM collar. These collars are 
made with a chemical called amitraz which is a topical anti-parasitic. These collars prevent tick 
attachment and if a tick does happen to attach itself to the dog, it kills the tick in less than 24 hours to 
prevent transmission of the B. burgdorferi bacteria. PreventicTM Collars are 97% effective against ticks 
for up to 3 months of use (Littman, 2006). However, just as with all other topical products, because 
amitraz is a harsh chemical there is a chance that it can cause some skin irritation such as a rash or even 
hair loss. Another important warning when using this product is that amitraz is a monoamine oxidase 
inhibitor, a powerful antidepressant drug. Humans who are on MAOI’s that are applying this product to 
their dog need to take extra precaution (Drugs.com Veterinary Edition, 2010).  
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Figure 15. PreventicTM Tick Collar made by Virbac.   
http://www.drsfostersmith.com/product/prod_display.cfm?pcatid=1254. 
 
Topical monthly tick control medications include FrontlineTM and AdvantixTM. FrontlineTM 
contains a chemical called Fipronil that is absorbed into the skin but does not enter the bloodstream. 
Fipronil blocks the passage of chlorine through the cell membranes of the insect causing the tick to 
become paralyzed (Nash, 2010). It is also an antiparasitic which kills ticks after their second day of 
attachment. The effects of FrontlineTM only last approximately a month however and it’s recommended 
that reapplication takes place every 30 days. AdvantixTM is also a topical solution which contains the 
chemicals imidicloprid and permethrin. It works in a similar way to FrontlineTM in that it kills ticks, 
however unlike FrontlineTM, it is also able to repel ticks from attaching in the first place.  AdvantixTM’s 
two active ingredients use similar modes of action to kill ticks. Both chemicals interfere with the nervous 
system of an attached insect; however imidicloprid blocks nerve receptors while permethrin causes 
repetitive nerve impulse firings (Nash, 2010).  
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Figure 16. FrontlineTM and K9 AdvantixTM, used as Tick Preventatives in Dogs.  
http://www.petcarerx.com/pcrx/ProductPages/Product.aspx?pid=13040&k=Frontline%20Plus%2
0One%20Year%20Supply%20Special. 
 http://cheap4you.wordpress.com/. 
 
If a dog should by chance ingest some of these chemicals the owner should call poison control. Just as 
with PreventicTM collars, these are strong chemicals and can cause damage if not used properly. Also, 
there is also a chance that both of these tick preventatives could cause skin irritation such as a rash or skin 
loss (Drugs.com Veterinary Edition, 2010).  
 
Figure 17. Rash that Developed on a Canine's Skin due to an Allergic Reaction to AdvantixTM.  
http://www.elversonpuzzle.com/advantix.jpg. 
 
Due to the fact that cats tend to clean themselves more than dogs do, they are at a greater risk of 
ingesting these topical insecticides which are poisonous if ingested. For this reason, only certain tick 
preventatives can be used safely on cats. Also many products are made to work specifically with the 
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canine physiology and many of these chemicals are easily digested by dogs while cats are unable to 
metabolize them (National Pesticide Information Center, 2010).  
Much controversy has been raised over whether or not people should have their dogs vaccinated 
for Lyme disease. Although there is the possibility of adverse reactions to the vaccination, the benefits of 
vaccination have been shown to outweigh the cons. The first factor that should come into consideration is 
whether or not the dog resides in an endemic area. Most dogs that do not live in areas where the Lyme 
prevalence is high will not need the Lyme disease vaccination. Also many small dogs that do not go 
outside often and are at a lower chance of getting infected may not need to receive the vaccine either. 
Many owners are worried about adverse reactions their pet may have to the vaccine but studies have 
shown that less than 2% of dogs who have received the vaccine had adverse reactions (Littman, 2006). 
Dogs can be lethargic the day or two after vaccination, but this is a typical side effect of most 
vaccinations. This is similar to how humans are sore the day or two after they receive an immunization. 
Once a dog is started with the Lyme vaccine it should receive an annual booster for the rest of their life, 
unless they become infected.  
 There are currently three Lyme vaccinations available for use in dogs. LymeVaxTM is made by 
Fort Dodge Animal Health, RECOMBITEKTM Lyme, made by Merial, and Galaxy LymeTM which is 
made by Schering-Plough Animal Health. The RECOMBITEKTM Lyme vaccine, made by Merial, works 
by generating anti-OspA antibodies which kill the B. burgdorferi within the tick. A study was done to test 
the efficacy of the Osp-A vaccine. Three months after the study had begun,  9 of the 11 (82%) control 
canines were Lyme positive, whereas none of the vaccinated dogs tested positive during that time span 
and continued to be Lyme negative a year after the study began (Wikle, 2006). LymeVaxTM made by Fort 
Dodge and Galaxy LymeTM made by Schering-Plough Animal Health are bacterin vaccines, meaning that 
that actually have a small amount of weakened B. burgdorferi bacteria in them. The vaccine introduces 
the immune system to the bacteria at a low level to mount a primary immune response. Should the dog 
get naturally infected later in life the secondary response to the bacteria will be much faster and efficient. 
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A study similar to the one performed using the RECOMBITEKTM Lyme vaccine was done to test the 
efficacy of the bacterin vaccine. This study has a larger test group and all dogs in the study lived in the 
Connecticut River Valley area, a highly endemic location for Lyme disease. The results showed that 64% 
of non-vaccinated dogs had been infected and only 5% of the dogs who had been vaccinated annually 
with the bacterin vaccine tested Lyme positive (Levy, 2002).   
If a dog is a good candidate for receiving the Lyme vaccine, they would typically be started with 
their first booster at 9 or 12 weeks of ago. They would then receive a second booster 2 to 4 weeks after 
the initial vaccine. From then on, the dog would receive the Lyme vaccine on an annual basis. However, a 
dog should be tested for Lyme before the vaccine is administered (Battiston, 2010). As Dr. Tanya 
Battiston DVM explains, “An infected dog, in theory, could be at higher risk for complications if they 
were given a vaccine when their immune system is already exposed, and fighting the infection.  We are 
concerned about auto-immune consequences.” The most important consideration to take into account 
when deciding whether or not to vaccinate your dog if you live in an endemic area, is that if you do not 
vaccinate them and they become infected, even after treatment your household pet has become a reservoir 
animal for Borrelia burgdorferi (Littman, 2006). Once your dog has become a reservoir animal for Lyme 
disease, they could then potentially pass the disease onto you.      
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Table 2. Pros and Cons of Canine Lyme Vaccination 
 
http://www3.interscience.wiley.com/cgi-
bin/fulltext/120715308/PDFSTART?CRETRY=1&SRETRY=0. 
 
Methods for Reducing Tick Population 
 
 The infectivity of deer ticks is completely dependent on their reservoir mammal hosts. Many 
proactive methods of reducing the tick population in endemic areas of the country have been postulated, 
however most ideas are too expensive or inhumane to be used widespread. Controlling the population of 
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the white-tailed deer would be easiest due to their size and the fact that they are already hunted for sport. 
The white-footed mouse is more difficult to control because of its smaller size and its ability to reproduce 
quickly (CCELD, 2010).  
 The normal deer population for Connecticut was calculated to be 10 deer per square mile of land. 
According to the Connecticut Coalition to Eradicate Lyme Disease (CCELD) by simply reducing the deer 
population to normal levels will help eradicate Lyme disease.  
 
Figure 18. Graph Showing the Decline in the Number of Deer Tick Nymphs due to Reduction of the Deer Population to Natural 
Levels.  
http://www.eradicatelymedisease.org/lyme.html. 
 
 
 Another preventative method that has been in use in some areas are the ‘4 Poster’ Deer Treatment 
Bait Stations. The device was invented by the Argiculture Research Service branch of the USDA and was 
patented in 1994. These stations attract deer with whoel kernel corn and when the deer eats the bait, 
rollers apply 10% permethrin tickicide to the deers ears. Research has found that 90% of adult feeding 
ticks attach to a deers ears or the deers head area. When the deer groom themselves they can also spread 
the tickicide to other areas of their bodies. Studies have shown that using this device can decrease the 
free-living tick population by 92-98% over a time span of three years. This Lyme disease control method 
is being used in the Northeast region of the U.S. as well as in Maryland and Texas (ALDF, 2010). It 
serves as a promising method for controlling tick populations due to its humane mechanism of action and 
its lack of disturbance to the ecosystem.   
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Figure 19. 4 Poster Deer Treatment Bait Station 
http://www.aldf.com/fourPoster2.shtml. 
  
Figure 20. The figure on the right shows the number of attached ticks on a deer's ears before treatment and the figure on 
the left shows the absence of ticks after treatment. 
http://www.aldf.com/fourPoster2.shtml. 
 
Public Health / Prevention  
 
We certainly will not be able to accurately predict exactly when or where the next major zoonotic 
disease will spring-up, or even what type of infection for that matter. We can hypothesize where the next 
major outbreak might occur based on factors like regional population densities, economics, and proximity 
to animals. However, these factors are not always absolute indicators of a zoonotic outbreak, as was the 
case with Lyme disease developing in a rural economically prosperous area. The emergence of a new 
zoonotic can be viewed as a phenomenon, a “perfect storm”, where all of the conditions required for 
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disease propagation are present. This is why public health organizations are placing more efforts into 
preventing and controlling the spread of infectious diseases as opposed to predicting where and when they 
will emerge. Fighting the spread of zoonotic diseases, whether new or reemerging, is an uphill battle that 
begins first with a positive identification of a disease outbreak. Prompt recognition and response to a 
zoonotic threat can make the difference between a few localized cases to a global pandemic. Minimizing 
the amount of time it takes to identify and respond to an outbreak can be accomplished through effective 
communication between different public health organizations.  
In order to understand how information related to zoonotic diseases (or simply infectious diseases 
in general) gets passed on, we must first understand the structure of the public health system. At its most 
basic level, the public health system begins in a doctor’s office or veterinary clinic, where the practitioner 
positively diagnoses a person or animal with a “reportable disease”. The practitioners then report the 
incident to local town public health boards, who then report the incident to the state department of public 
health (DPH). The state DPH will then monitor the number of cases reported throughout the state, while 
providing support to the local public health boards in dealing with the potential outbreak. If the disease 
begins affect a large population within the state, the state DPH will then repost the cases to the Centers for 
Disease Control and Prevention (CDC). The CDC is a federally funded organization that has national 
jurisdiction when it comes to matters of public health (especially emerging infectious diseases). If the 
disease begins to spread throughout a larger region of the United States, the CDC may notify the World 
Health Organization (WHO) about the epidemic. The WHO a UN sponsored organization that monitors 
public health and disease prevention on a global scale, and it is at the top of the public health’s chain of 
command.  
This is ideally how disease information is passed on in the public health system. However, in 
reality communication and information sharing between public health organizations can be an obstacle. In 
the United States the infrastructure of public health can be described as a convoluted web of jurisdictions 
and policies. The public health system in this country has evolved over the centuries, and it was not 
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always governed at the federal and state levels. In fact informal local public health boards existed long 
before any official public health departments were established. Because of this, each local and even state 
department of public health has its own way of doing things.  “As a whole, we (public health 
organizations) do a pretty good job of passing on information about the prevalence of certain diseases 
within our jurisdiction”, says Dr. Catherine Brown who is Massachusetts’s state public health 
veterinarian. She went on to say that information sharing between state public health departments is often 
informal and done over the phone. However there is no standard database that all of the states or local 
health departments input data into  
Varying policies between public health organizations is just one of the factors that inhibit the 
flow of disease related information. Another example is the concept of which diseases are reportable and 
which ones are not. Exactly which diseases are reportable vary between regions and states, and also 
between humans and animals. For example, positive identification of Lyme disease in humans is 
reportable but it is unrepeatable in animals. This variation in the reportability of a disease can cause a 
misrepresentation the prevalence of a disease within both human and animal populations. Social and 
economic barriers also inhibit the flow of zoonotic information sharing in the public health system. This 
is especially true with animal healthcare. Dr. George Saperstein, a large animal veterinarian at Tufts 
University’s School of Veterinary Medicine, described this concept well by providing an anecdote, 
“As a large animal veterinarian who has discovered a salmonella infection in a single 
cow, I would be pressed with an ethical dilemma. On one hand the farmer is my 
client and my source of income; should I report him and potentially get his farm shut 
down by department of agriculture? On the other hand I would not want the 
salmonella infection to spread further into the animal or human population. As 
veterinarians we take an oath to protect both animal and human health, and these are 
the types of dilemmas we face on a regular basis.”     
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Figure 21. Maps Showing the Increasing Prevalence of Lyme Disease in the United States Over the Past Two Decades.  
http://www.avhnj.com/nss-folder/pictures/lymemap.gif. 
 
 
Education  
  
 One of the main roles a health care professional must fill is the role of educator. If a 
physician or veterinarian simply treats a patient for an ailment and never takes the time to 
educate that patient or patient’s owner, they have not fully done their job. It is essential to make 
people aware of the health risks they face in order to help them create a disease-free life style for 
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themselves. Treatment alone may work over the short term, but education is needed in order to 
ensure a reoccurrence of disease or re-infection in the future. Many times this education entails 
recommendations for behavior modification.  While interviewing faculty members from 
Cummings School of Veterinary Medicine, in addition to a small animal veterinarian and the 
State Public Health Veterinarian of Massachusetts, the reoccurring theme of our discussions was 
education as a means of disease prevention and control. Dr. Catherine Brown of the 
Massachusetts DPH described how the Principle of KBA (Knowledge, Behavior, and Attitudes) 
affects prevention of disease. She explained that Lyme disease is still on the rise in humans, even 
though it is a widely known and well studied disease. The main factor that contributes to its 
continued state as an uncontrolled infectious disease is that it is not a fatal disease in most cases 
and therefore has been given lower priority in comparison to health risks such as cancer.   
 In order to spread education and awareness of Lyme disease to our college campus, the 
IQP team put together an educational flyer. This flyer contained the basic facts about Lyme 
disease in humans and dogs and important information on prevention. The flyer was distributed 
at the Pre-Health Formal dinner to Pre-Health students and Biology department faculty members 
and  distributed at the WPI Health Services office. A representative from the Health services 
office welcomed the educational flyers and said, “Education- that’s what we’re all about!”  
38 
 
 
Figure 22. Handout that was Generated to Educate the Public on Human and Canine Lyme Disease and its Prevention. 
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Human and Canine Overlap  
 
 As with many other zoonotic and vector-borne diseases, there is more than just one side 
to this disease. Treating a person or dog that presents with Lyme disease only solves half of the 
problem at hand. Unless prevention and control methods are put in place and applied, the disease 
will continue to spread. Where the disease originates from and how it is transmitted needs to be 
taken into consideration in order to proactively prevent the disease. Establishing a method for 
controlling the movement of Lyme disease from its reservoir hosts, to a human or dog is required 
in addition to treatment of the disease itself. However, while attempting to accomplish this, the 
impact any of these control methods might have on the environment must be taken into 
consideration as well.  
 When the IQP team met with Dr. George Saperstein from the Cummings School of 
Veterinary Medicine, Dr. Saperstein stressed the importance of a “One Health” approach to 
medicine that is essential for the control of all zoonotic diseases.  He explained that this approach 
strives to maintain the health of humans, animals, and ecosystems all together. Since humans, 
animals and the environment all impact each other, working towards optimal health for all three 
will create a healthier world for everyone.  
 While Ben researched all aspects of Lyme disease in humans, and Carrie researched all 
aspects of Lyme disease, many overlaps were found. Some of the symptoms experienced by 
humans were similar to the clinical symptoms that dogs exhibit as well. Diagnostic methods and 
testing were also similar with the use of ELISA blood tests, and treatment using antibiotic 
regimens is almost identical in both species. While discussing these similarities and differences, 
the IQP team decided to create a Venn diagram of the human and canine overlap in Lyme 
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disease. This is just further illustration of how vital it is to understand some aspects of veterinary 
medicine as a human physician, and vice versa.  
 
 
Figure 23. Venn Diagram of Human and Canine Lyme Disease Comparison. 
 
Interactive Project Element  
 
 At a dinner held by the Mu Sigma Delta Pre-Health Society at WPI, on April 20th, 2010, 
the IQP team gave a lecture on Lyme disease. In attendance were Pre-Health students, mainly 
Pre-Medical and Pre-Veterinary students, as well as WPI Biology and Biotechnology 
Department faculty, and some Health care professionals from the community.  The Health care 
professionals were a mix of human medicine and veterinary medicine professionals. The IQP 
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team decided this would be an excellent forum for discussing a disease that is so widely 
acknowledged yet continues to be on the rise.  
 
Figure 24. IQP Team giving a talk on Lyme Disease at the Pre-Health Formal Dinner at WPI. 
 
Not only were all facets of Lyme disease in both humans and dogs discussed, but the IQP team 
also stressed the importance of education as a prevention method of disease and the importance 
of an overlap in human and animal medicine. A PowerPoint presentation was made from all of 
the compiled research. While the IQP team had the attention of local doctors and veterinarians as 
well as future doctors and veterinarians, the ideal opportunity was discovered to share the 
relevant information found while researching zoonotics and Lyme disease. After giving some 
background on zoonotics, history of Lyme disease, and explaining how it is transmitted, Ben 
discussed how a Borrelia burgdorferi infection affects humans. Carrie then took over and 
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explained how a Lyme infection is dealt with when a dog presents to a veterinarian with the 
common clinical symptoms of Lyme disease. The IQP team wrapped up the lecture by speaking 
about the importance of education when controlling disease and preventing infection or even re-
infection. Also discussed was the need for a greater synergy between human and animal health 
care in order to combat zoonotic diseases, which are currently on the rise.  
 
ZOONOTIC DISEASES 
IN SOCIETY TODAY:
LYME DISEASE
By: Carrie Ellsworth and Ben Nagle
Advisor: Prof. Eric Overstrom
 
Figure 25. Title slide of PowerPoint presentation on Lyme Disease. 
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Appendix  
 
1.) Interview with Dr. Giovanni Widmer from Cummings School of 
Veterinary Medicine at Tufts University 
 
Questions for Dr. Widmer:  
CARRIE 
-What specifically interests you about zoonotic diseases?  
-Do you believe that the importance of educating people about zoonotic diseases has been 
understated in current society especially due to its prevalence right now?   
-What do you believe is the greatest contribution to the spread of zoonoses?  
-What do you consider to be the greatest zoonotic threat facing the world today? 
 -Do you believe that more emphasis should be put into studying emerging animal diseases and 
pathogens to prevent their possible spread to humans in the future?  
-(If yes) What specific area of zoonoses should be more extensively studied?  
-Can you tell us about the research you are currently working on with Cryptosporidium and  
Giardia and what you are hoping to achieve?  
-How effective do you believe the giardia vaccine is in terms of reducing the spread and re-
infection of giardia?  
BEN 
-What other medical methods, besides vaccination, have proven to be affective against the spread 
of zoonotic derived diseases? 
-Who controls the distribution and production of vaccines? Is it strictly the federal government, 
or are there private companies authorized to produce vaccine? 
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-What are the regulations for the importation of live/butchered animals into the US? What are the 
policies in other countries?  
-What are the socioeconomic effects of a global zoonotic disease pandemic? 
-How do different countries deal with epidemics and are those methods successful? 
-When studying virulent Zoonotic pathogens in the lab, what security measures must be taken?  
-What do you believe is the most effective method for controlling the spread of zoonotic derived 
diseases?  
 
Notes from Meeting with Dr. Widmer:       12/11/09 
-Level 2 Lab on campus not yet up and running so people are allowed to walk through  
Current Research: 
 -Cryptosporidia 
• What genes determine certain properties/ which genes confer certain traits 
• Investigating treatments options 
 Cell line which works as indicator 
 Fluorescence stain  
 Episome (plasmid) transfected 
 Promoter responds to presence of protozoa 
-Giardia 
• High throughput system 
• Molecular markers test cysts 
• Micro-ray analysis 
• Vaccine most likely passive and introduces fixed tropozoites to body  
Focus of paper:  
• -Specific area of the world  
• -Form of transmission 
• -Emergent diseases (ex. Ebola)  
• Host range (predicting path /mutations) 
 
Major Contributors to spread of zoonoses:  
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• Movement/ importing of animals  
• New types due to immune-compromised patients 
• Environmental degradation 
• Deforestation  
• Antibiotic resistance of livestock due to over use  
• Difficult to control  
*Preventative measures important in aiding in reduction of zoonoses 
-Influenza strains are the greatest zoonotic threats today because they easily and quickly mutate 
and because of antibiotic resistant bacteria 
-Education helped reduce the spread of HIV  
-Current technology is not keeping us from discovering new emerging pathogens 
Examples of interesting areas in zoonotic disease:  
• Rift Valley Fever (Africa) 
• Sleeping Sickness (Africa)  
 Sterile male Tse Tse flies used to compete with fertile males and decrease 
tse tse fly population  
• Origin of Malaria (Evolutionarily) 
 
 
2.)  Interview with Dr. George Saperstein from Cummings School of Veterinary 
Medicine at Tufts University 
 
Questions for Dr. George Saperstein: 
-Tell us about your research that you did in Asia with the avian flu.  
-I read that you have also done some work in the Middle East to control the spread of disease in 
livestock. Could you tell us what specifically you were working with there?  
-I saw that listed under your general research areas was xenotransplantation. This is a term that 
came up a couple times during my research and I was very interested in exploring. Can you tell 
us a little bit about that?  
-Do you believe that the importance of educating people about zoonotic diseases has been 
understated in current society especially due to its prevalence right now?   
-What do you believe is the greatest contribution to the spread of zoonoses?  
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-What do you consider to be the greatest emerging disease facing the world today? 
 -Do you believe that more emphasis should be put into studying emerging animal diseases and 
pathogens to prevent their possible spread to humans in the future?  
-(If yes) What specific area of zoonoses should be more extensively studied?  
- It seems like emerging infectious disease scares disappear from public concern over time (ex 
Bird flu, SARS, and more recently H1N1). Is this due to the success of Public Health 
Organizations, or just the natural decline in the prevalence of the pathogen? Dose the media play 
a role? 
- It seems like we were successful at controlling the recent H1N1 outbreak. In your opinion why 
were we successful and what could we have done better?   
- As a veterinarian, how would you go about reporting an incident of a potential threat to public 
health? Who are the governing bodies in Public Health at the local, state, federal, and global 
levels?  
-What other medical methods, besides vaccination, have proven to be affective against the spread 
of zoonotic derived diseases? 
-What are the regulations for the importation of live/butchered animals into the US? What are the 
policies in other countries?  
-How do different countries deal with epidemics and are those methods successful? 
-What do you believe is the most effective method for controlling the spread of zoonotic derived 
diseases? 
Meeting with Dr. Saperstein:      1/25/10 
-Animals-> Humans-> Animals transmission possible 
Ex. MERSA  
-USDA in charge of keeping animals (especially livestock) healthy  
Developments that contributed to decrease in spread of zoonoses/ would help: 
-sewer systems 
-chlorination of water  
*Emphasis switched from infectious disease to non-infectious diseases/ health concerns  
(ex. cancer and smoking) 
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Funding is provided to fix problems not prevent them  
*Infectious disease control in animals (livestock) means greater profit for agriculture workers  
In veterinary medicine the current trend is prevention of disease instead of treatment  
(Breeding is being done to prevent disease) 
*In 1900’s USDA attempted to eradicate brucellosis and tuberculosis (both transmitted around or 
through milk)- programs that were established to do this are still in existence even though both 
have been almost completely eradicated 
*Animal exports are huge in US so public funds are allocated to animal health- this money goes 
to efforts to keep out diseases we don’t have (ex. Foot and Mouth Disease)  
*17% of US population has jobs that depend on agriculture  
*Economics play a big role in disease control because of the impact a disease outbreak could 
have on importation/exportation business  
2 Mammalian Sources of zoonotic diseases: 
-domestic animals 
-wildlife (most most from these) 
Agroterrorism= sabotage of livestock health (bringing in Foot and Mouth disease)  
Dr, Saperstein’s work with H5N1 (Avian Flu) in Indonesia: 
-still a threat  
-media is simply tired of covering it and human mortality rates have dropped  
-still prevalent in Indonesia and Egypt (Dr. Saperstein worked on program in Indonesia)  
-Vietnam and Thailand were able to control H5N1 quickly  
-Dr. Saperstein’s job was to train animal workers and veterinarians how to respond to the disease 
and how to control the spread of it 
 *He had to work with the native peoples’ superstitions and respect their culture while 
introducing the science concepts behind the spread of zoonoses and educating the people 
 *70% of Indonesian people keep birds in their domestic setting  
What made H5N1 such a problem in Asia? 
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-The disease was spreading from commercial to domestic animals  
-Many humans were in very close contact with the diseased birds  
-The H5N1 reservoir was in animals but people were more concerned with treating 
humans even though it is cheaper and more effective to treat the birds that were spreading 
the disease before it jumps to humans  
*In the 1980’s the USDA killed a flock of birds found in Pennsylvania that were infected with 
H5N1- utilizing the “Stamping Out” method of dealing with an outbreak   
*Areas where zoonoses are most likely to spring up are areas that have a large wildlife 
population and the humans are encroaching on the wildlife habitats- these areas also have little 
infrastructure for dealing with disease outbreaks  
*Veterinarians in these “hotspot” areas need to be educated   
**“One Health Approach” = maintaining the health of Humans, Animals, and Ecosystems all 
together 
Dr. Saperstein’s work in the Middle East: 
- Part of the Camp David Accord with Egypt and Israel was that the US was to provide resources 
to improve livestock health and productivity (Palestine and Jordan were also added to this 
agreement because they were not as sophisticated as Egypt and Israel) 
-spread of diseases in Middle East is so prevalent because of the clustered boarding countries, the 
nomadic culture of the people with their ruminant livestock 
-Research and work was mainly directed at Foot and Mouth disease, Brucellosis, and small 
ruminant health issues (neonatal diseases)  
Xenotransplantation: 
-In the 1970’s experiments began with transplanting primate organs in humans 
-ethics was a concern because primates were being killed for their organs 
-the primate organs did not work well and were rejected 
-experiments began with swine organs because they are the next most anatomically similar non 
primate animal (less concern with ethics is the pig would have been sent to slaughter anyways) 
-The sugar α-gal is present on the surface of all swine cells however and human’s cells do not 
recognize these so organs were rejected 
-breeding of pigs without α-gal on their cell surface began (some was even being done at Tufts)  
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-neurons were also being harvested from fetal pigs to be injected into the brain of late stage 
Parkinson’s disease patients to bridge gaps in neuronal impulse propagation 
-then islet cells from fetal pigs were being harvested to transplant into diabetic patients pancreas’ 
-swine livers were being used to cleanse human blood in patient with liver failure 
*Many of these experiments did not get past FDA approval phase trials because there was not 
enough conclusive evidence 
**Endogenous retroviruses= pieces of old viruses that are part of our genomes 
Reporting Zoonotic Diseases in Animals: 
-If a veterinarian treats with antibiotics they could create animals who are carriers for the disease  
-Are the animals economically or medically worth treating? 
-Diagnostic labs should compile data and report cases  
-USDA inspects slaughterhouses at critical control points (Hazard Analysis)  
-Real time PCRs performed in plants to test food products  
Ways to prevent the spread of disease: 
-Vaccination 
 *Ring vaccination (vaccinate hotspot areas only instead of widespread vaccination)  
 *Plum Island, NY maintains banks of vaccine concentrate TOP SECRET 
-“Stamping Out” method  
*Mass Emergency Management Agency 
*1929 was the last outbreak of Foot and Mouth in the US and it occurred in Mass.  
Risk Communication: 
-not presenting the facts or accurate risks 
-attempting the squelch panic  
-media will twist medical professional’s words and misconstrue the facts 
*Import/export of animals covered by USDA-APHIS 
*World Trade Organization deals with animal products (tariffs) 
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*World Animal Health Organization (OIE) sets standards for animal disease control  
1918 Spanish Flu Pandemic had possible origins in animals and was spread during WWI due to 
the transportation of soldiers between continents  
**Educating public about zoonoses is vital but physicians need to be better educated as well 
**Need a better mix of Human and Animal Health  
3.) Interview with Dr. Jean Mukherjee from Cummings School of Veterinary 
Medicine at Tufts University 
 
Meeting with Dr. Mukherjee:       1/27/10 
Her background: 
-educated in microbiology and immunology 
-regulatory and selective agent work  
-monoclonal antibodies and small molecule therapeutics 
Other Zoonoses that a prevalent in New England area:  
-Leptosporosis 
-E. coli  
-Salmonella  
-Staph  
What to cover in our project:  
-Biology of Organism  
-Where it is in population  
-How it is transmitted 
-Tests for pathogen  
 *What are they testing? (Antibodies or antigens) 
-Differences between human and animal infection  
-How the organism and its host interact  
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Preventative measures and Treatment options:  
-Tick prevention  
*Frontline 
*Advantage ( imidacloprid ) 
*Revolution (selamectin)  
*Program and Sentinel tablets (lufenuron) 
-eradicate white-footed mice and deer 
-get rid of ticks 
-antibiotics (Doxycycline)  
-Lyme vaccine  
*Lyme vaccine currently in use for animals was once used for humans but was taken off the 
market for humans 
 
4.) Conference Call with Dr. Catherine Brown, State Veterinarian for The 
Massachusetts Department of Public Health 
 
Questions for Dr. Catherine Brown 
What is your role in the Mass DPH? 
How closely do you work with other state health officials in the region to combat regional threats 
to public health? 
Who falls under your jurisdiction, and who would you report up to about matters pertaining to 
emerging infectious diseases? 
Do you see any flaws in the public health system, and if so how can they be addressed?  
Have zoonotic diseases presented a major problem for the state, over the past few years?  
Where does Lyme disease rank on your priority list as an emerging infectious disease? 
What measures has the state taken to try and limit the spread of Lyme disease? How effective 
have these methods been? 
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Are you familiar with the LIMErix vaccine for Borrelia bacteria, and if so why was it taken off 
of the market? Is there another vaccination in progress? 
   
What are some of the most pressing issues you are faced with in your job? 
What are some of the most prevalent zoonotic diseases in Massachusetts and are they different 
from neighboring states? 
Which zoonotic diseases do you continue to see and increase in and are still in the process of 
being controlled? 
Are there any zoonotic diseases that you predict we will see an outbreak in in the near future? 
Which wild animals present the biggest risk in terms of spreading diseases in Massachusetts? 
What types of restrictions and regulations does the state put on petting zoos and other areas 
where exotic animals are housed to prevent the spread of diseases or introduction of new 
diseases to the area? 
Can you tell us about the work you are doing with rabid coyotes and what advancements you are 
hoping to make or have made? 
What is the protocol for dealing with an animal that is suspected to be rabid? 
Once an animal tests positive for rabies what measures are taken next? 
What has been done in Rabies-free areas of the world to keep out or eradicate the disease? 
What can you tell us about the prevalence of Lyme disease in Massachusetts? 
 
Conference Call with Dr. Catherine Brown:                     2/10/10 
State Public Health Veterinarian: 
 -responsible for overseeing surveillance and education of public 
 -collects data, analyzes, figures out what risks are posed to humans, and educates people  
*Lyme disease tends to be separated out from zoonotic diseases with other vector-borne diseases  
Main Zoonoses and Vector-Borne Diseases in Mass.: 
1. Rabies 
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 -2-3 human deaths per year due to rabies  
 -1985 was last case of Rabies in Mass. And individual was infected outside of the state  
2. Lyme  
 -affects more individuals than Hepatitis A and B combined  
3. Tularemia 
 -Prevalent in Martha’s Vineyard  
4. Eastern Equine Encephalitis (EEE)  
*120 infectious diseases in Mass. , 42 of which are zoonotic  
Home Rule (Local jurisdiction)  
 -351 towns and each have their own local health dept 
 -each town has different protocols, opinions, and priorities 
Mass. Department of Public Health (State jurisdiction) 
CDC (Federal jurisdiction) 
No database to record diseases- human patient confidentiality prevents reporting most human 
diseases 
Reportable human diseases are reported to the DPH 
Reportable Animal diseases are reported to the Agriculture Dept 
*4 Reportable animal diseases- West Nile Virus, EEE, plague, and anthrax 
 
Lyme Disease:  
 -Ecological factors 
  *deer and mice populations 
  *human habitats 
 -humans indirectly responsible for spread  
 -people must take personal actions 
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  *wearing long sleeves and pants 
  *using tick repellants 
  *checking for ticks 
*Ecological modifications often lead to negative consequences 
KBA (Knowledge Behavior and Attitudes)  
 -pesticides (expensive) 
 -not fatal disease 
 -more concerned about other diseases or health threats 
*Climate change and distribution of different vectors 
Enteric Zoonoses most common- salmonella and E. coli  
Rabies:  
*Bats pose biggest risk 
*Can only test for Rabies post-mortem  
*Many island countries have never been exposed to Rabies and have managed to keep it out 
Behavioral signs of Rabies: 
-Furious Rabies (Aggressive) 
-Dumb Rabies (Sleepy) 
* Oral vaccine used for raccoons in Cape Cod 
*From the 1950’s to now huge improvements and advancements have been made with Rabies  
Human Vaccine: 
-3 series 
-Unpopular 
-came out during anti-vaccine movement 
-adverse reactions 
-reluctance to undertake project again due to failure 
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-made no money 
-no vaccine is currently close to clinical trial stage yet 
Imported Animals: 
 -strict regulations on testing  
 -quarantine period before being put in with other animals  
 -lots of hoops to jump through to import animals 
 -illegally imported animals are a larger and growing problem 
*Dept. of Agriculture  
*USDA 
*Dept. of Fish and Game  
Mass DPH offers recommendations to petting zoos in order to prevent spread of disease 
*Salmonella outbreak in Mass. School due to owl pellet dissection  
5.) Electronic interview with Dr. Tanya Battiston DVM who is co-owner and practitioner at 
a small animal practice in Farmington, CT 
Questions for Dr. Battiston:        3/17/10 
-How do you educate your clients about Lyme disease? 
 
 We spend a lot of time educating clients on prevention, control, etiology, signs, testing 
and treatment of Lyme disease. Our clinic has composed a protocol based off of the 2006 
ACVIM consensus on Lyme disease.  We give clients this handout and follow the protocol (see 
attached). We also discuss potential complications from the disease as well as availability of 
vaccinations to prevent disease. We stress tick control as the hallmark of prevention for Lyme 
disease.  We also explain that we need to test for Lyme disease, via 4DX, each year before 
vaccinating. 
 
 
-What suggestions do you make to your clients for how they can attempt to prevent their 
dog from contracting Lyme disease?  
 
 We explain that there is no method that is 100% at preventing Lyme disease in our 
Lyme endemic area.  Tick control, avoidance of tick habitats, careful landscaping, and daily 
checking for ticks is paramount in prevention.  Vaccination should be considered in high risk 
animals.  As deer ticks can be active year-round in our state, topical product to kill/repel ticks, 
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such as Preventic (amitraz) collars +/- Frontline (fipronil), Revolution(selamectin), Advantix 
(imidicloprid/) are recommended year-round. 
 
 
 
-What procedure do you normally follow when you have a dog present with the signs and 
symptoms that a veterinarian would associate with Lyme disease?  
 
 If history and physical examination findings are consistent with Lyme disease, we run a 
fast and easy, in-house blood test to confirm exposure (IDEXX 4DX snap test).  This tests for 
presence of a C 6 peptide that is present only in natural exposure or infection.  If this test is 
positive, we will run a Complete blood count, Serum Chemistry, urinalysis, and a Lyme 
Quantitative C6 peptide.  If positive for Lyme and symptomatic, we usually prescribe a 30 day 
course of Doxycycline +/- pain medication for comfort.  We would then screen this dog every 6 
months, for life, with a urinalysis and C 6 Quantitative analysis.  Our hope is that we will be 
able to identify, treat, and control dogs with active chronic Lyme, recrudescence of Lyme, or re-
infected dogs. 
 
 
What types of tests would you run? 
 See above  
 
 
-If a dog tests positive for Lyme disease how do you go about treating them and what 
recommendations would you make to their owner? 
 
 (See above) We treat the dog with a 30 day course of doxycycline, and then recheck the 
Lyme quantitative C6 +/-, a CBC, and urinalysis every 6 months to monitor, and retreat as 
symptoms recur.  
    
 
-Can you describe the Lyme vaccination protocol you follow for dogs at your clinic? Why 
do you cease administering the Lyme vaccination to a dog that has tested positive for 
Lyme?  
 
 *Lyme vaccine protocol would be started at 9 weeks of age or older with a series, 
starting with an initial vaccination followed by a booster 3 to 4 weeks later. If we start the 
vaccine at 6 months or younger, we do not need to Lyme test prior to vaccinating.  We then 
recommend retesting via 4DX every year prior to giving a booster. Lyme is not a core vaccine as 
determined by the AHAA vaccine guidelines for veterinarians.  As with any non-core 
immunization we have discussions of risk verses benefit with the owner.  We do not usually start 
adult dogs with Lyme vaccination as 70-90% of dogs in Connecticut have already been exposed. 
 We do not vaccinate dogs who have tested positive for the Lyme.  An infected dog, in 
theory, could be at higher risk for complications if they were given a vaccine when their immune 
system is already exposed, and fighting the infection.  We are concerned about auto-immune 
consequences.  This is exactly why we screen dogs for Lyme on the dog of their vaccination. 
61 
 
    
-Do you keep track of how many dogs that are patients at your clinic contract Lyme disease 
on a yearly basis? Have you noticed an increase in the number of Lyme positive dogs? 
 
 *No, we do not specifically track the dogs that contract Lyme disease on a yearly basis. 
However, we issue computer-generated reminders to clients who have patients with Lyme 
disease.  The reminded is every six months to have their animal’s Lyme C6 levels and urinalysis 
evaluated. 
 *Subjectively, we have noticed an increase in the number of asymptomatic dogs that 
test positive when we routinely test for Lyme disease via 4DX before re-vaccinating.  Most dogs 
in Connecticut will be exposed at sometime in their life 
 
  
-Why is it that you don’t hear much about cats getting Lyme disease? Are they able to 
contract the disease and just don’t exhibit the symptoms that dogs do? 
 
 *Cats can get Lyme disease, although it is extremely rare. Cats can seroconvert, but 
usually do not develop symptoms.  
 
 
-Do you believe that increased public education on Lyme disease would help decrease the 
prevalence of the disease (both in humans and animals) in the United States?  
 Educating people on tick control, avoidance of tick habits, regular tick checks and 
removal, as well as Lyme disease are important steps.  As a veterinarian, I believe that our 
hospital educates the public as well as possible relating to Lyme disease in dogs. I would like to 
see more human-related Lyme awareness from the human medical sector. 
 
